LIT-001 is the first nonpeptide oxytocin receptor (OT-R) agonist (EC50=55 nM; Ki=226 nM). LIT-001 improves social interaction in a mouse model of autism[1].
in vivo
LIT-001 (10-20 mg/kg; i.p.) alleviates core symptoms in the context of autism spectrum disorders (ASD )[1].
Animal Model:
Oprm1–/– mice (bred in house on a 50% 129SVPas–50% C57BL/6J hybrid background)[1]
Dosage:
10, 20 mg/kg
Administration:
i.p.
Result:
Alleviated core symptoms in the context of ASD.
References
[1] Frantz MC, et al. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. J Med Chem. 2018 Oct 11;61(19):8670-8692. DOI:10.1021/acs.jmedchem.8b00697
